Filing Details
- Accession Number:
- 0001209191-20-007671
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-07 18:35:45
- Reporting Period:
- 2020-02-05
- Accepted Time:
- 2020-02-07 18:35:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 914475 | Neurocrine Biosciences Inc | NBIX | Biological Products, (No Disgnostic Substances) (2836) | 330525145 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1643653 | Eric Benevich | 12780 El Camino Real San Diego CA 92130 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-05 | 1,145 | $103.11 | 16,279 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-05 | 809 | $102.90 | 17,007 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-06 | 1,395 | $101.48 | 18,262 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | Acquisiton | 2020-02-06 | 61,347 | $0.00 | 61,347 | $102.90 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2020-02-06 | 9,719 | $0.00 | 9,719 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 61,347 | 2030-02-06 | No | 4 | A | Direct | |
| 9,719 | No | 4 | A | Direct |
Footnotes
- Sale of 1,145 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,030) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.14 to $105.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Includes a total of 339 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan, consisting of 166 shares on February 28, 2019 and 173 shares on August 30, 2019.
- Sale of 809 shares of common stock issued upon vesting of 1,537 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (728) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.18 to $103.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.12 to $103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
- Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024.
Billionaire Hedge Funds
